Company / Free Cash Flow
LENZ Therapeutics, Inc. Free Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$70.0M
FY2025
5-year range
-$94.6M / -$58.6M
FY2021-FY2025
Trend
-16.9%
vs FY2024
Sector context
#86 of 194
Health Care
What the data says
At -$70M, LENZ Therapeutics, Inc.'s free cash flow ranks #86 of 194 in the Health Care sector. Declined from -$60M to -$70M over the past 2 years.
Based on SEC 10-K filings.
-$70M in FY2025.
Declined from -$60M to -$70M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#86 of 194 in Health CareTop 44% of 194This company -$70.0M Sector average $470.6M
▼
-114.9% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 16.9% year-over-year.
- Ranks #86 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2020.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$70.0M | -16.9% |
| FY2024 | -$59.9M | +0.9% |
| FY2023 | -$60.4M | +36.1% |
| FY2022 | -$94.6M | -61.4% |
| FY2021 | -$58.6M | -470.7% |
| FY2020 | -$10.3M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026